First-in-Human trial targets genetic root of fatty liver disease
NCT ID NCT05648214
Summary
This is a very early-stage study testing an experimental drug called ALN-PNP in healthy adults and people with a common fatty liver disease (MASLD). The main goal is to check the drug's safety, how the body processes it, and see if it can reduce liver fat. Researchers will also study its effects in people with a specific genetic variant linked to the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
California Clinical Trials Medical Group
COMPLETEDGlendale, California, 91206, United States
-
Genoma Research Group, Inc
RECRUITINGMiami, Florida, 33173, United States
-
Med Research of Florida, LLC
RECRUITINGMiami, Florida, 33186, United States
-
Pioneer Research Solutions
RECRUITINGHouston, Texas, 77099, United States
-
Tandem Clinical Research
RECRUITINGMarrero, Louisiana, 70072, United States
-
Velocity Clinical research
RECRUITINGLos Angeles, California, 90057, United States
Conditions
Explore the condition pages connected to this study.